Limits...
Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent.

Reimer P, Vosshenrich R - Biologics (2010)

Bottom Line: Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases.Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI.The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Klinikum Karlsruhe, Karlsruhe, Germany;

ABSTRACT
The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become a key technique for the characterization and detection of focal and diffuse liver disease. More recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and introduced in many countries. Gadoxetic acid may be considered a "molecular imaging" probe because the compound is actively taken into hepatocytes via the ATP-dependent organic anion transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI. The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

No MeSH data available.


Related in: MedlinePlus

Cholangiocellular carcinoma. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE C) and diffusion-weighted imaging (DWI) D) in the axial plane. A large central liver mass is demonstrated on unenhanced sequences. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) shows the lesion much better and additional satellite lesions in both liver lobes with increased conspicuity.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2921257&req=5

f5-btt-4-199: Cholangiocellular carcinoma. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE C) and diffusion-weighted imaging (DWI) D) in the axial plane. A large central liver mass is demonstrated on unenhanced sequences. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) shows the lesion much better and additional satellite lesions in both liver lobes with increased conspicuity.

Mentions: The purpose of this review is to provide an overview of the development, clinical testing, and applications (Figures 1–5) of this novel MR contrast agent.


Detection and characterization of liver lesions using gadoxetic acid as a tissue-specific contrast agent.

Reimer P, Vosshenrich R - Biologics (2010)

Cholangiocellular carcinoma. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE C) and diffusion-weighted imaging (DWI) D) in the axial plane. A large central liver mass is demonstrated on unenhanced sequences. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) shows the lesion much better and additional satellite lesions in both liver lobes with increased conspicuity.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2921257&req=5

f5-btt-4-199: Cholangiocellular carcinoma. Plain T1-weighted spoiled 2D gradient echo (GRE) A) T2-weighted half-Fourier acquisition single-shot turbo spin-echo (HASTE) B) hepatocellular phase gadoxetic acid-enhanced fat-suppressed (FS) T1-weighted spoiled 3D GRE C) and diffusion-weighted imaging (DWI) D) in the axial plane. A large central liver mass is demonstrated on unenhanced sequences. Gadoxetic acid-enhanced magnetic resonance imaging (MRI) shows the lesion much better and additional satellite lesions in both liver lobes with increased conspicuity.
Mentions: The purpose of this review is to provide an overview of the development, clinical testing, and applications (Figures 1–5) of this novel MR contrast agent.

Bottom Line: Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases.Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI.The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

View Article: PubMed Central - PubMed

Affiliation: Department of Radiology, Klinikum Karlsruhe, Karlsruhe, Germany;

ABSTRACT
The value of cross-sectional liver imaging is evaluated by the accuracy, sensitivity, and specificity of the specific imaging technique. Magnetic resonance imaging (MRI) has become a key technique for the characterization and detection of focal and diffuse liver disease. More recently, gadoxetic acid, the hepatocyte-specific MR contrast agent, was clinically approved and introduced in many countries. Gadoxetic acid may be considered a "molecular imaging" probe because the compound is actively taken into hepatocytes via the ATP-dependent organic anion transport system in the plasma membrane for the hepatic uptake. The transport of gadoxetic acid from the cytoplasm to the bile is mainly determined by the capacity of the transport protein glutathione-S-transferase. Gadoxetic acid enhances hepatocyte-containing lesions and improves detection of lesions devoid of normal hepatocytes, such as metastases. Innovative rapid MR acquisition techniques with near isotropic 3D pulse sequences with fat saturation parallel the technical progress made by multidetector computed tomography combined with an impressive improvement in tumor-liver contrast when used for gadoxetic acid-enhanced MRI. The purpose of this review is to provide an overview of the development, clinical testing, and applications of this novel MR contrast agent.

No MeSH data available.


Related in: MedlinePlus